Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Cautious on elevated broad-market valuations and rising rate pressures, leaning into high-quality healthcare and industrials while initiating longs in $GNRC, $RIG, and $ESAB.
Full Quick Take
Cautious on elevated broad-market valuations and rising rate pressures, leaning into high-quality healthcare and industrials while initiating longs in $GNRC, $RIG, and $ESAB.
Mott Capital underperformed in Q2 2026 as AI and semiconductor exuberance drove markets, but underlying portfolio businesses show strong fundamentals with cloud growth exceeding 35-40%.
Full Quick Take
Mott Capital underperformed in Q2 2026 as AI and semiconductor exuberance drove markets, but underlying portfolio businesses show strong fundamentals with cloud growth exceeding 35-40%.
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Full Quick Take
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Outperforming its benchmark by 570 basis points. AI infrastructure drove performance as the fund capitalized on accelerating investment in data center compute capacity, with Nebius Group and Credo Technology as top contributors.
Full Quick Take
Outperforming its benchmark by 570 basis points. AI infrastructure drove performance as the fund capitalized on accelerating investment in data center compute capacity, with Nebius Group and Credo Technology as top contributors.
Small cap fund underperformed in volatile Q1 2025 as trade tensions and AI competition concerns pressured markets. Portfolio benefited from Inari Medical's $4.7B Stryker acquisition and strong results from GeneDx and Guidewire, while Agilysys, Xometry, and FTAI detracted.
Full Quick Take
Small cap fund underperformed in volatile Q1 2025 as trade tensions and AI competition concerns pressured markets. Portfolio benefited from Inari Medical's $4.7B Stryker acquisition and strong results from GeneDx and Guidewire, while Agilysys, Xometry, and FTAI detracted.
Top contributors VSE, Palomar, and Progyny benefited from strong fundamentals and strategic actions, while detractors Semtech, Upstart, and Agilysys faced sector-specific headwinds.
Full Quick Take
Top contributors VSE, Palomar, and Progyny benefited from strong fundamentals and strategic actions, while detractors Semtech, Upstart, and Agilysys faced sector-specific headwinds.
ARK expects five innovation platforms - AI, robotics, energy storage, multiomics, and blockchain - to converge over the next decade, pulling the economy from rolling recession while creating deflationary forces.
Full Quick Take
ARK expects five innovation platforms - AI, robotics, energy storage, multiomics, and blockchain - to converge over the next decade, pulling the economy from rolling recession while creating deflationary forces.
Alger Small Cap Focus outperformed significantly in Q4 2024 with a 7.41% return versus 1.70% for Russell 2000 Growth. The focused 50-stock portfolio emphasizes secular growth themes including AI, cloud computing, and genomics.
Full Quick Take
Alger Small Cap Focus outperformed significantly in Q4 2024 with a 7.41% return versus 1.70% for Russell 2000 Growth. The focused 50-stock portfolio emphasizes secular growth themes including AI, cloud computing, and genomics.
Small-cap growth fund outperformed in Q4 2024 with 3.90% return, driven by AI-powered lending platform Upstart, genetic testing leader Natera, and semiconductor company Semtech. Portfolio focused on secular themes including AI, cloud computing, and genomic innovations.
Full Quick Take
Small-cap growth fund outperformed in Q4 2024 with 3.90% return, driven by AI-powered lending platform Upstart, genetic testing leader Natera, and semiconductor company Semtech. Portfolio focused on secular themes including AI, cloud computing, and genomic innovations.
Roughly in line with its benchmark. Despite near-term policy uncertainty under the new administration, the manager remains bullish on long-term health care innovation, particularly in biotechnology, medical devices, and life sciences tools.
Full Quick Take
Roughly in line with its benchmark. Despite near-term policy uncertainty under the new administration, the manager remains bullish on long-term health care innovation, particularly in biotechnology, medical devices, and life sciences tools.
Biotech funding dried up, hurting Charles River Labs, while software names like Guidewire showed recovery. The manager added genomics play Natera and maintains long-term conviction despite macro headwinds affecting growth company fundamentals.
Full Quick Take
Biotech funding dried up, hurting Charles River Labs, while software names like Guidewire showed recovery. The manager added genomics play Natera and maintains long-term conviction despite macro headwinds affecting growth company fundamentals.